Israel: These 29 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025

Generic name: vismodegib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: Israel Patent 181,673
Patent Title: תרכובות פירידילים מעכבים איתות במסלול hedgehog, תכשירים רוקחיים המכילים אותם, תהליך להכנתם ושימוש בהם להכנת תרופה לטיפול בסרטן (Pyridyl inhibitors of hedgehog signalling compounds, compositions comprising them, process for their preparation and use of said compounds for the manufacture of medicaments for treatment of cancer in a mammal)

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 07, 2024
Generic Entry Controlled by: Israel Patent 198,441
Patent Title: שיטות למניעת הריון בנקבות בשימוש במינונים הורמוניים עולים (Methods of female contraception using ascending hormonal dosages)

QUARTETTE is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has twenty-three patent family members in thirteen countries. There has been litigation on patents covering QUARTETTE

See drug price trends for QUARTETTE.

The generic ingredient in QUARTETTE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

Generic name: trabectedin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Israel Patent 182,776
Patent Title: COMPOSITIONS CONTAINING ECTEINASCIDIN AND A DISACCHARIDE

YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS

See drug price trends for YONDELIS.

The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.

Generic name: sapropterin dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2024
Generic Entry Controlled by: Israel Patent 182,161
Patent Title: STABLE FORMULATION COMPRISING A CRYSTALLINE POLYMORPH OF (6R)-L-ERYTHRO-TETRAHYDROBIOPTERIN DIHYDROCHLORIDE

KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and seventeen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN

See drug price trends for KUVAN.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.

Generic name: lamivudine; raltegravir potassium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Israel Patent 183,614
Patent Title: ANHYDROUS CRYSTALLINE POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR

DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has ninety-five patent family members in forty-three countries.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.

Generic name: raltegravir potassium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Israel Patent 183,614
Patent Title: ANHYDROUS CRYSTALLINE POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR

ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-five patent family members in forty-five countries.

See drug price trends for ISENTRESS.

The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.

Generic name: florbetaben f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2024
Generic Entry Controlled by: Israel Patent 183,946
Patent Title: STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES

NEURACEQ is a drug marketed by Life Molecular. There is one patent protecting this drug.

This drug has thirty-five patent family members in twenty-seven countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.

Generic name: florbetaben f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2024
Generic Entry Controlled by: Israel Patent 206,091
Patent Title: תולדות סטילבן והשימוש בהם לקשור ולשיקוף רבדי אמילואיד (Stilbene derivatives and their use for binding and imaging amyloid plaques)

NEURACEQ is a drug marketed by Life Molecular. There is one patent protecting this drug.

This drug has thirty-five patent family members in twenty-seven countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.

Generic name: lorcaserin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2024
Generic Entry Controlled by: Israel Patent 183,844
Patent Title: (r)-8-כלורו-1-מתיל-, 5 , 4, 3, 2- טטראהידרו-h 1-3- בנזאפין הידרוכלוריד המיהידרייט, תכשירים המכילים את המיהידרייט, תהליך להכנת ההמיהידרייט, תהליך לייצור תכשיר המכיל את ההמיהידרייט ושימושים בההמיהידרייט לייצור תרופה ((r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride hemihydrate, compositions comprising the hemihydrate, process for preparing the hemihydrate, process of making a composition comprising the hemihydrate and uses of the hemihydrate for the manufacture of a medicament)

BELVIQ is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has thirty-five patent family members in twenty-seven countries. There has been litigation on patents covering BELVIQ

See drug price trends for BELVIQ.

The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.

Generic name: levoketoconazole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2025
Generic Entry Controlled by: Israel Patent 184,459
Patent Title: תכשירי רוקחות המכילים אנאנטיאומר של s2, r4 קטוקונאזול לטיפול במחלות הנובעות מהגברת קורטיזול (Use of a 2s, 4r ketoconazole enantiomer for the preparation of medicaments for the treatment of elevated cortisol-mediated diseases)

RECORLEV is a drug marketed by Strongbridge. There are eight patents protecting this drug.

This drug has thirty-three patent family members in twenty-one countries.

See drug price trends for RECORLEV.

The generic ingredient in RECORLEV is levoketoconazole. One supplier is listed for this generic product. Additional details are available on the levoketoconazole profile page.

Generic name: methotrexate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 24, 2025
Generic Entry Controlled by: Israel Patent 184,765
Patent Title: PREFILLED NEEDLE ASSISTED JET INJECTOR

OTREXUP is a drug marketed by Otter Pharms. There are fourteen patents protecting this drug.

This drug has thirty-seven patent family members in fourteen countries. There has been litigation on patents covering OTREXUP

See drug price trends for OTREXUP.

The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

Generic name: crisaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Israel Patent 185,080
Patent Title: BORON-CONTAINING SMALL MOLECULES, PHARMACEUTICAL FORMULATIONS COMPRISING THEM AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING INFECTIONS

EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

Generic name: crisaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Israel Patent 192,402
Patent Title: מולקולות קטנות המכילות בורון (Boron-containing small molecules)

EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

Generic name: crisaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Israel Patent 207,156
Patent Title: מולקולות קטנות המכילות בור (Boron-containing small molecules)

EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

Generic name: tavaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Israel Patent 185,080
Patent Title: BORON-CONTAINING SMALL MOLECULES, PHARMACEUTICAL FORMULATIONS COMPRISING THEM AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING INFECTIONS

KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

Generic name: tavaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Israel Patent 192,402
Patent Title: מולקולות קטנות המכילות בורון (Boron-containing small molecules)

KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

Generic name: tavaborole
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 16, 2025
Generic Entry Controlled by: Israel Patent 207,156
Patent Title: מולקולות קטנות המכילות בור (Boron-containing small molecules)

KERYDIN is a drug marketed by Anacor Pharms Inc.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

Generic name: cabotegravir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: Israel Patent 186,555
Patent Title: (4r,9as)-5-הידרוקסי-4-מתיל-6,10-דיאוקסו-10,9a,9,6,4,3 -הקסאהידרו-2h-1-אוקסא-8a,4a -דיאזא אנטרצן-7-חומצה קרבוקסילית 4,2-דיפלואורו-בנזילאמיד או מלח רוקחי שלו, תכשיר המכיל אותו ושימוש בו בטיפול או מניעת hiv ((4 r,9as)-5-hydroxy-4-methyll-6,1 0-dioxo-3,4,6,9,9a ,10-hexahydro-2h-1-oxa-4a, 8a-diaza-anthracene-7 -carboxylic acid 2,4-difluoro-benzylamide or a pharmaceutically acceptable salt thereof, composition comprising it and uses thereof in the treatment and prophylaxis of hiv)

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

Generic name: cabotegravir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: Israel Patent 225,206
Patent Title: נגזרת של קרבאמוילפירידון רב-טבעתי, הרכב רוקחי המכיל אותה והשימוש בה (Polycyclic carbamoylpyridone derivative, pharmaceutical composition comprising the same and use thereof)

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

Generic name: cabotegravir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: Israel Patent 225,207
Patent Title: נגזרת של קרבאמוילפירידון רב-טבעתי, הרכב רוקחי המכיל אותה, השימוש בה ותהליך להכנתה (Polycyclic carbamoylpyridone derivative, pharmaceutical composition comprising the same, use and process for preparation thereof)

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

Generic name: sorafenib tosylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: Israel Patent 185,517
Patent Title: תכשיר רוקחות המכיל דיפניל אוריאה המותמר בקרבוקסיל בעמדה אומגה לטיפול בסרטן (Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer)

NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR

See drug price trends for NEXAVAR.

The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.

Generic name: semaglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: Israel Patent 184,051
Patent Title: תרכובות glp-1 שעברו אצילציה, תכשירי רוקחות המכילים אותן ושימוש בהן להכנת תרופות (Acylated glp-1 compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments)

OZEMPIC is a drug marketed by Novo. There are twenty-one patents protecting this drug.

This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC

See drug price trends for OZEMPIC.

The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

Generic name: semaglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: Israel Patent 184,051
Patent Title: תרכובות glp-1 שעברו אצילציה, תכשירי רוקחות המכילים אותן ושימוש בהן להכנת תרופות (Acylated glp-1 compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments)

WEGOVY is a drug marketed by Novo. There are six patents protecting this drug.

This drug has one hundred and twenty-eight patent family members in thirty-two countries. There has been litigation on patents covering WEGOVY

See drug price trends for WEGOVY.

The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.

Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: Israel Patent 186,656
Patent Title: METHOD OF CONTRACEPTION AND A CONTRACEPTION KIT

LO LOESTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has nine patent family members in seven countries. There has been litigation on patents covering LO LOESTRIN FE

See drug price trends for LO LOESTRIN FE.

The generic ingredient in LO LOESTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: Israel Patent 186,656
Patent Title: METHOD OF CONTRACEPTION AND A CONTRACEPTION KIT

LO MINASTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has nine patent family members in seven countries. There has been litigation on patents covering LO MINASTRIN FE

The generic ingredient in LO MINASTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Generic name: belinostat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: Israel Patent 187,231
Patent Title: הרכבים רוקחיים הכוללים מעכב היסטון דה-אצטילז וארגינין חופשי או מלח שלו, שימוש בהם ומוצרים המכילים אותם (Pharmaceutica l compositions of a histone deacetylase (hdac) inhibitor and free arginine or salt thereof' use thereof and products containing the same)

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

Generic name: belinostat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: Israel Patent 224,229
Patent Title: תכשיר רוקחי המכיל מעכב היסטון דה-אצטילז ומגלומין ושימוש בו ליצור תרופה (Pharmaceutical composition comprising a histone deacetylase inhibitor and meglumine and uses thereof in the manufacture of a medicament)

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

Generic name: enzalutamide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: Israel Patent 187,328
Patent Title: N-מתיל-2-פלואורו-{4-[3-(4-ציאנו-3-טריפלואורומתילפניל)-5,5-דימתיל-4-אוקסו-2-תיאוקסו-אימידאזולידינ-1-איל]}בנזאמיד, תכשירים רוקחים המכילים אותו ושימוש בו להכנת תרופות (N-methyl-2-fluoro-{4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]}benzamide, pharmaceutical compositions comprising the same and uses thereof in the manufacture of medicaments)

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

Generic name: enzalutamide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: Israel Patent 194,438
Patent Title: תרכובות דיארילתיוהידנטואין, תכשירים רוקחיים המכילים אותן, שיטות לסינתוזן ושיטות אין-ויטרו להבאתן במגע עם תאי יונקים (Diarylthiohydantoin compounds, pharmaceutical compositions comprising them, methods for their synthesis and in vitro methods for contacting them with mammalian cells)

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

Generic name: enzalutamide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: Israel Patent 258,880
Patent Title: תרכובות של דיארילהידנתוין (Diarylhydantoin compounds)

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-four patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

Generic name: bosentan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 17, 2025
Generic Entry Controlled by: Israel Patent 187,383
Patent Title: DISPERSIBLE BOSERTAN TABLET

TRACLEER is a drug marketed by Actelion. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has twenty-eight patent family members in twenty-three countries. There has been litigation on patents covering TRACLEER

See drug price trends for TRACLEER.

The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the bosentan profile page.

Generic name: bupropion hydrobromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: Israel Patent 185,760
Patent Title: הרכבים של מלח בופרופיון בעלי שחרור מותאמים (Modified-release formulations of a bupropion salt)

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries.

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

Generic name: famotidine; ibuprofen
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 18, 2025
Generic Entry Controlled by: Israel Patent 188,732
Patent Title: שימוש באיבופרופין ופאמוטידין להכנת תרופות (Use of ibuprofen and famotidine in the preparation of medicaments)

DUEXIS is a drug marketed by Horizon. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in fifteen countries. There has been litigation on patents covering DUEXIS

See drug price trends for DUEXIS.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the famotidine; ibuprofen profile page.

Generic name: famotidine; ibuprofen
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 18, 2025
Generic Entry Controlled by: Israel Patent 196,425
Patent Title: יחידת מינון למתן פומי המכילה איבופרופן ופאמוטידין (Oral unit dose form containing ibuprofen and famotidine)

DUEXIS is a drug marketed by Horizon. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in fifteen countries. There has been litigation on patents covering DUEXIS

See drug price trends for DUEXIS.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the famotidine; ibuprofen profile page.

Generic name: simeprevir sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 29, 2025
Generic Entry Controlled by: Israel Patent 188,227
Patent Title: תרכובות מקרוציקליות, שילובים ותכשירים רוקחיים המכילים אותן, שימושים בהן כמעכבי וירוס הפטיטיס c ותהליכים להכנתן (Macrocyclic compounds, combinations and pharmaceutical compositions comprising them, uses thereof as inhibitors of hepatitis c virus and processes for their preparation)

OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.

This drug has one hundred and thirty-nine patent family members in forty-three countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

Generic name: benzoyl peroxide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 02, 2025
Generic Entry Controlled by: Israel Patent 189,159
Patent Title: חיפוי של מתכת אוקסיד למרכיבים בלתי מסיסים במים (Metal oxide coating of water insoluble ingredients)

EPSOLAY is a drug marketed by Galderma Labs Lp. There are nine patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has twenty-eight patent family members in eleven countries.

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the benzoyl peroxide profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2025
Generic Entry Controlled by: Israel Patent 189,456
Patent Title: תהליך להכנת הרכב פרמצבטי לשחרור נשלט הכולל פנקראטין (Process for producing a controlled release pharmaceutical composition comprising pancreatin)

CREON is a drug marketed by

This drug has twenty-eight patent family members in eleven countries. There has been litigation on patents covering CREON

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2025
Generic Entry Controlled by: Israel Patent 189,457
Patent Title: תהליך שחול לייצור ליבות מיקרו כדוריות סנתטיות ללא שמן הכוללות פנקריאטין ופוליאתילן גליקול 4000 (Extrusion process for the manufacture of synthetic oil- free micropellet cores comprising pancreatin and polyethylene glycol 4000)

CREON is a drug marketed by

This drug has twenty-eight patent family members in eleven countries. There has been litigation on patents covering CREON

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: tolvaptan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: Israel Patent 189,481
Patent Title: תהליך עבור הפקת תרכובות 2,3,4,5-טטרההידרו-h1-1-בנזאזפין או מלחים מזה ותרכובת נקייה מאוד המופקת על ידי תהליך האמור (Process for producing 2,3,4,5-tetrahydro-1h-1- benzazepine compounds or salts thereof and highly pure compounds produced by said process)

JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE

See drug price trends for JYNARQUE.

The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

Generic name: tolvaptan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: Israel Patent 217,444
Patent Title: תהליך עבור תרכובות בנזאפין או מלחים מזה (Process for preparing benzazepine compounds or salts thereof)

JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE

See drug price trends for JYNARQUE.

The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

Generic name: tolvaptan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: Israel Patent 217,445
Patent Title: תהליך עבור ייצור תרכובת חומצה בנזאוית (Process for producing a benzoic acid compound)

JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE

See drug price trends for JYNARQUE.

The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

Generic name: tolvaptan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: Israel Patent 217,446
Patent Title: תכשיר רוקחי המכיל מרכיב פעיל מטוהר מאוד של 7- כלורו - 5 - הידרוקסי- 1- [2-מתיל-4-(2-מתילבנזואיל-אמינו)בנזואיל]-2, 3, 4, 5 - טטראהידרו- h 1 - 1 - בנזאזפין בעל טוהר של יותר מ - 99.5% או מלח שלו, או תכשיר רוקחות של מלח שלו (Pharmaceutical composition comprising as an active ingredient a highly pure 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methyl¬benzoyl¬amino)benzoyl]-2,3,4,5-tetrahydro-1h-1-benzazepine having a purity of more than 99.5 %, or a salt thereof, or a pharmaceutically acceptable salt thereof)

JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE

See drug price trends for JYNARQUE.

The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

Generic name: tolvaptan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: Israel Patent 222,396
Patent Title: תהליך הכנה תרכובת ל 4-(בנזואילאמינו) חומצה בנזואיק או מלחים שלהם (Process for preparing 4-(benzoylamino)benzoic acid compounds or salts thereof)

JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE

See drug price trends for JYNARQUE.

The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

Generic name: tolvaptan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: Israel Patent 189,481
Patent Title: תהליך עבור הפקת תרכובות 2,3,4,5-טטרההידרו-h1-1-בנזאזפין או מלחים מזה ותרכובת נקייה מאוד המופקת על ידי תהליך האמור (Process for producing 2,3,4,5-tetrahydro-1h-1- benzazepine compounds or salts thereof and highly pure compounds produced by said process)

SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA

See drug price trends for SAMSCA.

The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

Generic name: tolvaptan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: Israel Patent 217,444
Patent Title: תהליך עבור תרכובות בנזאפין או מלחים מזה (Process for preparing benzazepine compounds or salts thereof)

SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA

See drug price trends for SAMSCA.

The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

Generic name: tolvaptan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: Israel Patent 217,445
Patent Title: תהליך עבור ייצור תרכובת חומצה בנזאוית (Process for producing a benzoic acid compound)

SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA

See drug price trends for SAMSCA.

The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

Generic name: tolvaptan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: Israel Patent 217,446
Patent Title: תכשיר רוקחי המכיל מרכיב פעיל מטוהר מאוד של 7- כלורו - 5 - הידרוקסי- 1- [2-מתיל-4-(2-מתילבנזואיל-אמינו)בנזואיל]-2, 3, 4, 5 - טטראהידרו- h 1 - 1 - בנזאזפין בעל טוהר של יותר מ - 99.5% או מלח שלו, או תכשיר רוקחות של מלח שלו (Pharmaceutical composition comprising as an active ingredient a highly pure 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methyl¬benzoyl¬amino)benzoyl]-2,3,4,5-tetrahydro-1h-1-benzazepine having a purity of more than 99.5 %, or a salt thereof, or a pharmaceutically acceptable salt thereof)

SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA

See drug price trends for SAMSCA.

The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

Generic name: tolvaptan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: Israel Patent 222,396
Patent Title: תהליך הכנה תרכובת ל 4-(בנזואילאמינו) חומצה בנזואיק או מלחים שלהם (Process for preparing 4-(benzoylamino)benzoic acid compounds or salts thereof)

SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA

See drug price trends for SAMSCA.

The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.

Generic name: pirfenidone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2025
Generic Entry Controlled by: Israel Patent 189,273
Patent Title: תצורה קפסולרית של פירפנידון וחומרי תרופה בלתי-פעילים המתאימים מבחינה פרמצבטית (Capsule formulation of pirfenidone and pharmaceutically acceptable excipients)

ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has two hundred and sixty-three patent family members in forty-five countries. There has been litigation on patents covering ESBRIET

See drug price trends for ESBRIET.

The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.